RecruitingNCT06238700
Pregnenolone or placebo for perimenopausal depression
About this title
Read the official source — NCT06238700Placebo comparisonAges 40–60United States
Understand this study
Who could participate?
Listed age limits: 40 years to 60 years.
What will I do during this study?
Participants take pregnenolone or placebo (an inactive comparison treatment) twice daily for four weeks. The study examines behavioral and brain measures during the menopause transition.
- Listed locations
- BostonSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 1, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 80
- Sponsor
- Beth Israel Deaconess Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Other
- Intervention type
- Dietary supplement, Other
- Locations
- United States
- Age range
- From 40 Years to 60 Years
- Official registry ID
- NCT06238700
- Official title
Show the full official title
Targeting Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms That Underlie Depression in Women Across the Menopause Transition
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Beth Israel Deaconess Medical Center, a hospital or academic medical center.
Who can participate?
Listed age limits: 40 years to 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
